WRSs2

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

ImmunisationShigella Infection

Phase 1

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

CompletedNCT01336699

National Institute of Allergy and Infectious Diseases (NIAID)Shigella Infection

Start: 2013-01-07End: 2015-05-12Updated: 2019-01-28

Phase 2

Phase 2 Shigella Vaccine and Challenge

CompletedNCT04242264

National Institute of Allergy and Infectious Diseases (NIAID)Immunisation, Shigella Infection

Start: 2022-10-12End: 2024-07-08Updated: 2026-08-10

Related Papers

Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding

PLoS ONE2021-11-186 citations